News | January 16, 2025
Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
Morepen Laboratories approves hiving off of medical devices business
Morepen Laboratories approves hiving off of medical devices business
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The scheme is fully digitized and covers approximately 45% of India's population
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Biocon Biologics remains committed to global standards of quality and compliance
Investment will fund expansion to meet rising demand for CRDMO services
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Subscribe To Our Newsletter & Stay Updated
